Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
Notice for trametinib (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
trametinib
Date of review outcome
Lapse date
Type
Priority review
Indication
Trametinib, in combination with dabrafenib, is indicated for the adjuvant treatment of patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.
Registration date